Omada Health opened lower at $15.06, compared with its previous close of $15.24. In the last trading session, the stock traded between $14.63 and $15.17. It showed a downward intraday trend.
An investment of $100 made 2 years ago in Omada Health is now worth
$ 63.97
Resulting in a loss of
$ 36.03 (36.03%)
Note: Past profits do not guarantee future returns.
Rating from 10 Analysts
Today's Change
$-0.53 (-3.46%)
Day High
$15.17
Day Low
$14.63
Day Open
$15.06
Prev Close
$15.24
Volume
6,97,723
1W Return
-24.24%
1M Return
-32.72%
3M Return
-38.69%
6M Return
0.16%
1Y Return
-29.30%
Market Cap ($ Mn)
913
PE Ratio
98.75
PB Ratio
5.68
PEG Ratio
-
ROE
-
ROCE
-8.83%
EPS (TTM)
-
1 Week
-24.24%
1 Month
-32.72%
3 Months
-38.69%
6 Months
0.16%
9 Months
34.49%
Wells Fargo lowers Omada Health price target to $19, maintains equal-weight
Wells Fargo lowered Omada Health price target from $22 to $19. Analyst Stan Berenshteyn maintained an Equal-Weight rating. Price target reduction amounts to $3 per share.
6 days agoOmada Health Q3 revenue rises 34% to $91 million on member growth
Revenue grew 34% YoY to $91 million, exceeding expectations due to early enrollments and program mix shift. Net income reached nearly $7 million, a $10 million improvement from a loss in the prior year quarter. Full-year FY26 revenue guidance raised to $344 million-$346 million, implying 33% growth at midpoint. Total members increased 36% YoY to 1.134 million, with average tenure rising to 28 months. Cost of care per member dropped to an all-time low of $81, driving gross margin expansion to 76%.
7 days agoOmada Health Q2FY26 Results: Revenue up 43% YoY to $88 million
Revenue rose 43% YoY to $88 million, setting a quarterly record. Adjusted EBITDA reached $11 million, swinging from a loss last year. Total members grew 45% YoY to approximately 1.1 million. Full-year revenue guidance raised to $334-340 million. CEO transition announced: Wei-Li Shao to succeed Sean Duffy in January 2027.
1mo agoBTIG reiterates Buy on Omada Health, keeps $35 target
BTIG analyst David Larsen reiterates Buy rating on Omada Health. Price target remains unchanged at $35 per share. Action reflects stable outlook for NASDAQ-listed OMDA.
2mo agoAnalysts raise Omada Health price targets to $27 and $28
Citizens analyst Constantine Davides maintained Omada Health with a Market Outperform rating and raised the price target to $27 from $21. Canaccord Genuity analyst Richard Close also maintained a Buy rating and increased the price target to $28 from $24.
3mo agoOmada Health to join Canaccord Genuity's 46th Annual Growth Conference
Omada Health's senior management will attend Canaccord Genuity’s 46th Annual Growth Conference in Boston, featuring a fireside chat on August 11, 2026. The company offers virtual care for chronic conditions and has served over two million members. A live webcast and replay will be available on its investor relations website.
4mo ago| Stock | LTP | Change % | Market Cap | PE |
|---|---|---|---|---|
| $506.04 | +0.32% | $1,05,708.21M | 14.01 | |
| $304.77 | -0.26% | $49,345.01M | 45.36 | |
| $292.97 | +0.93% | $23,316.90M | 10.31 | |
| $72.62 | +0.18% | $14,450.29M | 52.31 | |
| $79.43 | -1.38% | $14,087.55M | - | |
| $142.24 | -0.19% | $13,957.16M | 20.21 | |
| $22.22 | -2.29% | $11,935.03M | 11.93 | |
| $183.50 | +2.35% | $11,542.15M | 15.26 | |
| $186.19 | +0.59% | $10,862.51M | 27.11 | |
| $196.77 | +0.70% | $10,170.65M | 7.00 | |
| $103.03 | -0.49% | $8,522.13M | 34.79 | |
| $50.06 | +1.96% | $7,945.72M | 25.00 |
An investment of $100 made 2 years ago in Omada Health is now worth
$ 63.97
Resulting in a loss of
$ 36.03 (36.03%)
Note: Past profits do not guarantee future returns.
